Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP solriamfetol crossover study in obstructive sleep apnea with excessive daytime sleepiness and cognitive impairment
NL-OMON50853Phase 4Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Jazz Pharmaceuticals plc. Started Jun 2021; status: active, not recruiting.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON50853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50853.